Rosemary Crane's Insider Trades & SAST Disclosures
Rosemary Crane's most recent trade in Certara Inc was a trade of 15,757 Restricted Stock Units done . Disclosure was reported to the exchange on May 21, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Rosemary Crane.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Certara Inc | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 15,757 | 15,757 | - | - | Restricted Stock Units | |
| Certara Inc | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 11,928 | 0 | - | - | Restricted Stock Units | |
| Certara Inc | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 11,928 | 29,915 | - | 0 | Common Stock | |
| Tarsus Pharmaceuticals Inc | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 3,350 | 5,350 | - | - | Common Stock | |
| Tarsus Pharmaceuticals Inc | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 3,350 | 0 | - | - | Restricted Stock Units | |
| Teva- Pharmaceutical Indus... | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 21,108 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 21,108 | 103,615 (0%) | 0% | - | Ordinary Shares | |
| Tarsus Pharmaceuticals Inc | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 3,350 | 3,350 | - | - | Restricted Stock Units | |
| Teva- Pharmaceutical Indus... | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 9,632 | 9,632 | - | - | Restricted Share Units | |
| Certara Inc | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 11,928 | 11,928 | - | - | Restricted Stock Units | |
| Certara Inc | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2024 | 8,663 | 17,987 | - | 0 | Common Stock | |
| Certara Inc | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2024 | 8,663 | 0 | - | - | Restricted Stock Units | |
| Catalent Inc. | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2023 | 6,993 | 23,873 (0%) | 0% | 0 | Common Stock | |
| Tarsus Pharmaceuticals Inc | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 3,350 | 3,350 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 2,000 | 2,000 | - | - | Common Stock | |
| Tarsus Pharmaceuticals Inc | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 2,000 | 0 | - | - | Restricted Stock Units | |
| Certara Inc | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2023 | 9,324 | 9,324 | - | 0 | Common Stock | |
| Certara Inc | Rosemary A. Crane | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2023 | 9,324 | 0 | - | - | Restricted Stock Units | |
| Certara Inc | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 8,663 | 8,663 | - | - | Restricted Stock Units | |
| Catalent Inc. | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 4,149 | 16,880 (0%) | 0% | 0 | Common Stock | |
| Certara Inc | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2022 | 9,324 | 9,324 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 7,000 | 7,000 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Catalent Inc. | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 1,402 | 12,731 (0%) | 0% | 0 | Common Stock | |
| Tarsus Pharmaceuticals Inc | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2021 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Catalent Inc. | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 2,125 | 11,329 (0%) | 0% | 0 | Common Stock | |
| Catalent Inc. | Rosemary A. Crane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2020 | 661 | 9,204 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges